Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › CPX-351

CPX-351

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of CPX-351

7 trials tracked of CPX-351: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 210 citations.

7Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 6
  1. Phase 3 Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Completed · 210 cited
  2. Phase 2 Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia Completed
  3. Phase 2 Trial of CPX-351 in Newly Diagnosed Elderly AML Patients Completed
  4. Phase 2 Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) Completed
  5. Phase 2 Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Completed
  6. Phase 2 Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia Completed
Show 1 more trials
  1. Phase 2 An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
CPX-351 improves survival in AML with myelodysplasia-related changes
Oncology RCT
CPX-351 improves survival in AML with myelodysplasia-related changes New leukemia treatment works best for specific gene type
This randomized phase 3 trial in 184 patients with AML and myelodysplasia-related mutations evaluated CPX-351 versus standard cytarabine plu…
A leukemia drug thought to help many patients actually works only in those with a specific genetic subtype, leaving others in need of better…
Apr 29, 2026
CPX-351 first-line therapy shows 61% overall response in therapy-related AML or AML with myelodysplastic-related changes
Oncology Cohort
CPX-351 first-line therapy shows 61% overall response in therapy-related AML or AML with myelodysplastic-related changes New AML Drug Shows Strong Response But Some Patients Face Higher Risk
This retrospective monocentric cohort study evaluated 60 consecutive patients treated with CPX-351 as first-line therapy for therapy-related…
A new leukemia drug helps most patients respond well, but those with high white blood cell counts or complex gene changes may face higher ri…
Frontiers Apr 27, 2026